NCT06660264

An Evaluation of the Impact of Pharmacist Personalized Medication Reviews With and Without a Discussion of Pharmacogenomic Results in an Employee Health Program.

Implementing Risk-Based Preemptive Pharmacogenomic (PGx) Testing in Employee Health

• Status: Enrolling By Invitation
• Phase: N/A
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: University of Pittsburgh · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this prospective randomized clinical trial is to learn if a pharmacist-provided personalized medication review (PMR) that discusses pharmacogenomic test results will improve medication outcomes. The primary aim is to identify patients within the Pitt/UPMC employee health programs who are most likely to benefit from PGx testing based on prescription history. The second aim is to determine the effect of the pharmacist-provided PMR including PGx test results. Participants 18 years of age and older who have undergone PGx testing through a independent biobanking study (Pitt+Me Discovery) will be randomly assigned to receive PMR with a discussion of PGx test results or PMR without PGx results. Those who receive PMR only will receive PGx results one year after their PMR. Researchers will compare the groups to see if a pharmacist-provided PMR using PGx test results will lead to better medication outcomes and lower medical costs.

Conditions

• Pharmacogenetics
• Pharmacogenomic Drug Interaction

Interventions

Type	Name	Description
OTHER	Pharmacist Personalized Medication Review (PMR)	Pharmacist-provided review of current medications and assessment of potential medication related problems.
OTHER	Discussion of Pharmacogenomic results during the PMR	Return of pharmacogenomic results and discussion of impact on medications.

Timeline

• Start date: 2025-01-15
• Primary completion: 2027-06-30
• Completion: 2027-06-30
• First posted: 2024-10-28
• Last updated: 2025-10-30

Locations

1 site across 1 country: United States